natgillin/translations-raw huggingface dataset:
Da der ikke foreligger kliniske data om eksponering for clopidogrel under graviditet, foretrækkes det, af.clopidogrel ikke anvendes under graviditet af sikkerhedsmæssige årsager. 
As no clinical data on exposure to clopidogrel during pregnancy are available, it is preferable not to use clopidogrel during pregnancy as a precautionary measure.
CYP2C19*1 allelen svarer til en fuldt funktionel metabolisme, mens CYP2C19*2 og CYP2C19*3 allelerne ikke er funktionelle. 
The CYP2C19*1 allele corresponds to fully functional metabolism while the CYP2C19*2 and CYP2C19*3 alleles are nonfunctional.
Lejlighedsvis anvendelse af acetylsalicylsyre (højst 1000 mg i løbet af et døgn), et stof der findes i mange lægemidler, der anvendes til at lindre smerter og sænke feber, bør generelt ikke give problemer. 
An occasional use of acetylsalicylic acid (no more than 1000 mg in any 24 hour period), a substance present in many medicines used to relieve pain and lower fever, should generally not cause a problem, but prolonged use in other circumstances should be discussed with your doctor.
Der var ingen signifikant forskel mellem grupperne i det primære sammensatte endepunkt død, shunttrombose eller hjerterelateret intervention før 120-dages-alderen efter en hændelse betragtet som værende af trombotisk art (89 [19,1%] i clopidogrelgruppen og 90 [20,5%] i placebogruppen) (se pkt. 
There was no significant difference between groups in the primary composite endpoint of death, shunt thrombosis or cardiac-related intervention prior to 120 days of age following an event considered of thrombotic nature (89 [19.1%] for the clopidogrel group and 90 [20.5%] for the placebo group) (see section 4.2).
- tegn på leverproblemer såsom gulfarvning af huden og/eller øjnene (gulsot), uanset om det sker i forbindelse med blødninger, som viser sig under huden som små røde prikker, og/eller forvirring (se afsnit 2 'Vær ekstra forsigtig med at tage Clopidogrel Qualimed”). 
- signs of liver problems such as yellowing of the skin and/or the eyes (jaundice), whether or not associated with bleeding which appears under the skin as red pinpoint dots and/or confusion (see section 2 ‘Take special care with Clopidogrel Qualimed').
Denne nedgang var associeret med en 39 % (initial mætningsdosis) og 21 % (vedligeholdelsesdosis) reduktion i trombocythæmning. 
The decrease was associated with a 39% (loading dose) and 21% (maintenance dose) reduction of inhibition of platelet aggregation.
Clopidogrel forlænger kapillærblødningstiden og bør anvendes med forsigtighed hos patienter med læsioner, der indebærer øget blødningstendens (specielt gastrointestinalt og intraokulært). 
Clopidogrel prolongs bleeding time and should be used with caution in patients who have lesions with a propensity to bleed (particularly gastrointestinal and intraocular).
Clopidogrel er testet in vitro og in vivo i en række genotoksicitetsforsøg og udviste ingen genotoksisk aktivitet. 
Clopidogrel has been tested in a range of in vitro and in vivo genotoxicity studies, and showed no
• skal De også straks fortælle det til Deres læge, hvis De udvikler en medicinsk tilstand (Trombocytisk Trombocytopenisk Purpura eller TTP), der giver feber og blå mærker under huden, der kan fremstå som røde små prikker, med eller uden uforklarlig udtalt træthed, forvirring, gulfarvning af huden eller øjnene (gulsot) (se afsnit 4”Bivirkninger”). 
• You should also tell your doctor immediately if you develop a medical condition (also known as Thrombotic Thrombocytopenic Purpura or TTP) that includes fever and bruising under the skin that may appear as red pinpoint dots, with or without unexplained extreme tiredness, confusion, yellowing of the skin or eyes (jaundice) (see section 4 ‘Possible side effects').
Som forholdsregel bør amning ophøre under behandling med Clopidogrel Qualimed. 
As a precautionary measure, breast-feeding should not be continued during treatment with Clopidogrel Qualimed.
Der der dog foretaget et antal retrospektive analyser for at evaluere denne effekt hos patienter i behandling med clopidogrel, for hvem der foreligger resultater af genotyping: CURE (n=2.721), CHARISMA (n=2.428), CLARITY-TIMI 28 (n=227) og TRITON-TIMI 38 (n=1.477) såvel som et antal publicerede kohortestudier. 
There have been a number of retrospective analyses, however, to evaluate this effect in patients treated with clopidogrel for whom there are genotyping results: CURE (n=2721), CHARISMA (n=2428), CLARITY-TIMI 28 (n=227), TRITON-TIMI 38 (n=1477), and ACTIVE-A (n=601), as well as a number of published cohort
.Data fra CAPRIE-studiet indikerer, at phenytoin og tolbutamid, som metaboliseres af CYP2C9, uden risiko kan administreres samtidig med clopidogrel uden risiko. 
Data from the CAPRIE study indicate that phenytoin and tolbutamide which are metabolised by CYP2C9 can be safely co-administered with clopidogrel.
Farmakoterapeutisk klassifikation: Trombocytfunktionshæmmende midler eksklusive heparin, ATCkode: B01AC-04. 
Pharmacotherapeutic group: platelet aggregation inhibitors excl. heparin, ATC code: B01AC-04.
På grund af risikoen for blødning og hæmatologiske bivirkninger bør det med det samme overvejes at kontrollere blodstatus og/eller foretage andre passende prøver, hvis der opstår kliniske symptomer, der tyder på blødninger i løbet af behandlingen (se pkt. 
Due to the risk of bleeding and haematologicaladverse reactions, blood cell count determination and/or other appropriate testing should be promptly considered whenever clinical symptoms suggestive of bleeding arise during the course of treatment (see section 4.8).
Heparin: I et klinisk studie med raske forsøgspersoner gav clopidogrel ikke anledning til ændring af heparindosis og det forandrede ikke heparins virkning på koagulationen. 
Heparin: in a clinical study conducted in healthy subjects, clopidogrel did not necessitate modification of the heparin dose or alter the effect of heparin on coagulation.
Graviditet og amning Det er bedst ikke at tage denne medicin under graviditet og amning. 
Pregnancy and breast-feeding It is preferable not to take this product during pregnancy..
Der blev ikke observeret nogen virkning på levermetaboliseringsenzymerne hos mennesker, der havde fået clopidogrel i terapeutiske doser. 
No effect on hepatic metabolising enzymes was observed in humans receiving clopidogrel at the therapeutic dose.
Clopidogrel reducerede signifikant forekomsten af nye iskæmiske tilfælde (kombineret endepunkt, der omfattede myokardieinfarkt, iskæmisk apopleski og vaskulær død) ved sammenligning med ASA. 
Clopidogrel significantly reduced the incidence of new ischaemic events (combined end point of myocardial infarction, ischaemic stroke and vascular death) when compared to ASA.
Lægemidler, der hæmmer CYP2C19, inkluderer omeprazol og esomeprazol, fluvoxamin, fluoxetin, moclobemid, voriconazol, fluconazol, ticlopidin, ciprofloxacin, cimetidin, carbamazepin, oxcarbazepin og chloramphenicol. 
Medicinal products that inhibit CYP2C19 include omeprazole and esomeprazole, fluvoxamine, fluoxetine, moclobemide, voriconazole, fluconazole, ticlopidine, ciprofloxacin, cimetidine, carbamazepine, oxcarbazepine and chloramphenicol.
In vitro og in vivo bliver clopidogrel metaboliseret via to primære veje: En esterasemedieret, hvorved det hydrolyseres til dets inaktive carboxylsyrederivat (85 % af de cirkulerende metabolitter) og en medieret af flere cytochrom P450isoenzymer. 
In vitro and in vivo, clopidogrel is metabolised according to two main metabolic pathways: one mediated by esterases and leading to hydrolysis into its inactive carboxylic acid derivative (85% of circulating metabolites), and one mediated by multiple cytochromes P450.
Der foreligger ikke beviser for, at andre lægemidler, der reducerer mavesyren, såsom H2-blokkere (med undtagelse af cimetidin, der er en CYP2C19-hæmmer) eller antacida, påvirker clopidogrels antitrombotiske aktivitet. 
There is no evidence that other medicinal products that reduce stomach acid such as H2 blockers (except cimetidine which is a CYP2C19 inhibitor) or antacids interfere with antiplatelet activity of
Hos de patienter, som alene indgik i studiet på grund af et nyligt myokardieinfarkt, lå clopidogrel numerisk lavere, men ikke statistisk forskelligt fra ASA (RRR = -4,0%, CI: -22,5 til 11,7 [p=0,639]). 
In patients who were enrolled in the trial on the sole basis of a recent myocardial infarction, clopidogrel was numerically inferior, but not statistically different from ASA (RRR = -4.0%; CI: -22.5 to 11.7 [p=0.639]).
Hvis De glemmer at tage en tablet i over 12 timer, skal De blot tage den næste enkeltdosis til sædvanlig tid. 
If you forget for more than 12 hours, simply take the next single dose at the usual time.
Hvis De ammer eller planlægger at amme, skal De tale med Deres læge, før De tager denne medicin. 
If you are breastfeeding or planning to breastfeed, talk to your doctor before taking this medicine.
Trombotisk trombocytopenisk purpura (TTP) 
Thrombotic Thrombocytopenic Purpura (TTP)
I nogle enkelte tilfælde er der indberettet blødning i øjet, i hovedet, lungerne eller leddene. 
In a small number of cases, bleeding in the eye, inside the head, the lung or the joints has also been reported.
Hvis der observeres blødning, bør passende behandling overvejes. 
Appropriate therapy should be considered if bleedings are observed.
I TRITON-TIMI 38 og 3 af kohortestudier (Collet, Sibbing, Giusti), havde den kombinerede gruppe af patienter med status som enten intermediate eller poor metaboliser en højere hyppighed af kardiovaskulære hændelser (død, myokardieinfarkt og apopleksi) eller stenttrombose sammenlignet med personer med extensive metabolisme. 
In TRITON-TIMI 38 and 3 of the cohort studies (Collet, Sibbing, Giusti) the combined group of patients with either intermediate or poor metaboliser status had a higher rate of cardiovascular events (death, myocardial infarction, and stroke) or stent thrombosis compared to extensive metabolisers.
• Voksne og ældre Clopidogrel bør gives som en enkelt daglig dosis på 75 mg. 
Clopidogrel should be given as a single daily dose of 75 mg.
Det er karakteriseret ved trombocytopeni og mikroangiopatisk hæmolytisk anæmi i forbindelse med enten neurologiske fund, renal dysfunktion eller feber. 
It is characterised by thrombocytopenia and microangiopathic haemolytic anaemia associated with either neurological findings, renal dysfunction or fever.
Selvom administration af 75 mg clopidogrel daglig ikke ændrede S-warfarins farmakokinetik eller International Normalised Ratio (INR) hos patienter i langtidsbehandling med warfarin, øgede samtidig administration af clopidogrel og warfarin blødningsrisikoen på grund af uafhængig effekt på hæmostasen. 
Although the administration of clopidogrel 75 mg/day did not modify the pharmacokinetics of S-warfarin or International Normalised Ratio (INR) in patients receiving long-term warfarin therapy, coadministration of clopidogrel with warfarin increases the risk of bleeding because of independent
Et cross-over studie med 40 raske forsøgspersoner, 10 i hver af de fire CYP2C19-metaboliser- grupper (ultrahurtig, extensive, intermediate eller poor), evaluerede farmakokinetisk og trombocythæmmende respons ved dosering af 300 mg efterfulgt af 75 mg/dag og 600 mg efterfulgt af 150 mg/dag, hver i alt 5 dage (steady state). 
A crossover study in 40 healthy subjects, 10 each in the four CYP2C19 metaboliser groups (ultrarapid, extensive, intermediate and poor), evaluated pharmacokinetic and antiplatelet responses using 300 mg followed by 75 mg/day and 600 mg followed by 150 mg/day, each for a total of 5 days (steady state).
Herudover blev clopidogrels farmakodynamiske aktivitet ikke påvirket signifikant af samtidig administration af phenobarbital, eller østrogen. 
Furthermore, the pharmacodynamic activity of clopidogrel was not significantly influenced by the coadministration of phenobarbital, or oestrogen.
Den gennemsnitlige blødningstid var endvidere ens i de to grupper. 
The mean bleeding time prolongation was also similar in the two groups.
Hvis De har glemt at tage Clopidogrel Qualimed Hvis De har glemt en dosis af Clopidogrel Qualimed, men kommer i tanke om det i løbet af 12 timer, skal De omgående tage tabletten og dernæst tage den næste tablet til sædvanlig tid. 
If you forget to take a dose of Clopidogrel Qualimed, but remember within 12 hours of your usual time, take your tablet straightaway and then take your next tablet at the usual time.
Den aktive tiolmetabolit, som er blevet isoleret in vitro, binder hurtigt og irreversibelt til blodpladereceptorerne, hvorved trombocytaggregation hæmmes. 
The active thiol metabolite which has been isolated in vitro, binds rapidly and irreversibly to platelet receptors, thus inhibiting platelet aggregation.
• hvis De har en nyre- eller leversygdom 
• if you have kidney or liver disease.
Hungary Mylan Kft Tel: 36 1 8026993 
Mylan Kft Tel: 36 1 8026993
Specifikke farmakokinetiske forsøg med radioaktivt mærket clopidogrel har vist, at udgangsstoffet eller dets metabolitter udskilles i mælk. 
Specific pharmacokinetic studies performed with radiolabelled clopidogrel have shown that the parent compound or its metabolites are excreted in the milk.
I et randomiseret, dobbelblindt, parallelgruppestudie (CLARINET) blev 906 pædiatriske patienter (nyfødte og spædbørn) med cyanotisk kongenit hjertesygdom palliativt opereret med en systemisk-tilpulmonalarterie shunt randomiseret til at få clopidogrel 0,2 mg/kg (n=467) eller placebo (=439) med samtidig standardbehandling indtil tidspunktet for 2. stadie-kirurgi. 
In a randomised, double-blind, parallel-group study (CLARINET), 906 paediatric patients (neonates and infants) with cyanotic congenital heart disease palliated with a systemic-to-pulmonary arterial shunt were randomised to receive clopidogrel 0.2 mg/kg (n=467) or placebo (n=439) along with concomitant background therapy up to the time of second stage surgery.
Hvis De bliver gravid, mens De tager Clopidogrel Qualimed, skal De omgående kontakte Deres læge, da det frarådes at tage clopidogrel under graviditet. 
If you become pregnant while taking Clopidogrel Qualimed, consult your doctor immediately as it is recommended not to take clopidogrel while you are pregnant.
Den gennemsnitlige maksimale plasmakoncentration af uomdannet clopidogrel (ca. 2,2-2,5 ng/ml efter en enkelt oral dosis på 75 mg) indtraf ca. 45 minutter efter dosering. 
Mean peak plasma levels of unchanged clopidogrel (approximately 2.2-2.5 ng/ml after a single 75 mg oral dose) occurred approximately 45 minutes after dosing.
Ved mindre sår og skader, som hvis De f.eks. skærer Dem under barbering, er dette som regel ikke noget problem. 
For minor cuts and injuries e.g., cutting yourself, shaving, this is usually of no concern.
Meget sjældne bivirkninger: Gulsot; alvorlige mavesmerter med eller uden rygsmerter; feber, åndedrætsbesvær ind imellem i ledsaget af hoste; generelle allergiske reaktioner; hævelse i munden; blærer på huden; hudallergi; betændelse i munden (stomatitis); blodtryksfald; forvirring; hallucinationer; ledsmerter; muskelsmerter; smagsforstyrrelser. 
Very rare side effects: Jaundice; severe abdominal pain with or without back pain; fever, breathing difficulties sometimes associated with cough; generalised allergic reactions; swelling in the mouth; blisters of the skin; skin allergy; inflammation of the mouth (stomatitis); decrease in blood pressure; confusion; hallucinations; joint pain; muscular pain; changes in the way things taste..
Der er indrapporteret inkonsistente data fra både observationsstudier og kliniske studier vedrørende de kliniske konsekvenser af denne farmakokinetiske (PK)/farmakodynamiske (PD) interaktion med hensyn til alvorlige kardiovaskulære hændelser. 
Inconsistent data on the clinical implications of this pharmacokinetic (PK)/pharmacodynamic (PD) interaction in terms of major cardiovascular events have been reported from both observational and clinical studies.
Desuden var IPA på 32 % (24 timer) og 61 % (dag 5), hvilket var større end hos personer med poor metabolisme, der fik 300 mg/75 mg-regimet, og svarede til IPA ved 300 mg/75 mg regimet hos de andre grupper af CYP2C19metabolisers. 
In addition, IPA was 32% (24 hours) and 61% (Day 5), which were greater than in the poor metabolisers receiving the 300 mg/75 mg regimen, and were similar to the other CYP2C19 metaboliser groups receiving the 300 mg/75 mg regimen.
Hvis De er gravid eller har mistanke om, at De kan være gravid, skal De fortælle det til Deres læge eller på apoteket, før De tager Clopidogrel Qualimed. 
If you are pregnant or suspect that you are pregnant, you should tell your doctor or your pharmacist before taking Clopidogrel Qualimed.
Kontakt Deres læge eller apoteket, før De holder op. 
Contact your doctor or pharmacist before
Test er tilgængelige til at identificere en patients CYP2C19genotype. 
Tests are available to identify a patient's CYP2C19 genotype.
CAPRIE-studiet omfattede 19.185 patienter med aterotrombose manifesteret ved nyligt myokardieinfarkt (<35 dage), nyligt iskæmisk apopleski (mellem 7 dage og 6 måneder) eller påviste perifere kredsløbsforstyrrelser (PAD). 
The CAPRIE study included 19,185 patients with atherothrombosis as manifested by recent myocardial infarction (<35 days), recent ischaemic stroke (between 7 days and 6 months) or established peripheral arterial disease (PAD).
Der blev ikke fundet fertilitetspåvirkning hos rotter af begge køn, og clopidogrel udviste ingen teratogen virkning hos rotter eller kaniner. 
Clopidogrel was found to have no effect on the fertility of male and female rats and was not teratogenic in either rats or rabbits.
Antacida påvirkede ikke omfanget af absorptionen af clopidogrel. 
Antacids did not modify the extent of clopidogrel absorption.
I et dosiseskaleringsstudie med 86 nyfødte eller spædbørn op til 24 måneder med risiko for trombose (PICOLO) blev clopidogrel evalueret ved konsekutive doser på 0,01, 0,1 og 0,2 mg/kg til nyfødte og spædbærn og ved 0,15 mg/kg alene til nyfødte. 
In a dose escalation study of 86 neonates or infants up to 24 months of age at risk for thrombosis (PICOLO), clopidogrel was evaluated at consecutive doses of 0.01, 0.1 and 0.2 mg/kg in neonates and infants and 0.15 mg/kg only in neonates.
Ved behov for hurtig behandling af forlænget kapillærblødningstid kan en trombocytinfusion muligvis modvirke virkningen af clopidogrel. 
If prompt correction of prolonged bleeding time is required, platelet transfusion may reverse the effects of clopidogrel.
CYP2C19 er involveret i dannelsen af såvel den aktive metabolit, som mellemstadiemetabolitten 2oxo-clopidogrel. 
CYP2C19 is involved in the formation of both the active metabolite and the 2-oxo-clopidogrel intermediate metabolite.
NAVN PÅ INDEHAVEREN AF MARKEDSFØRINGSTILLADELSEN Qualimed 
NAME OF THE MARKETING AUTHORISATION HOLDER
I intention-to-treat-analysen blev der observeret 939 tilfælde i clopidogrelgruppen og 1.020 tilfælde i ASA-gruppen (relativ risikoreduktion (RRR) 8,7 % [95 % CI: 0,2-16,4], p=0,045), hvilket for hver 1000 patienter, der blev behandlet i 2 år, svarer til, at yderligere 10 [CI: 0-20] patienter beskyttes mod et nyt iskæmisk tilfælde. 
In the intention to treat analysis, 939 events were observed in the clopidogrel group and 1,020 events with ASA (relative risk reduction (RRR) 8.7%, [95% CI: 0.2 to 16.4]; p = 0.045), which corresponds, for every 1000 patients treated for 2 years, to 10 [CI: 0 to 20] additional patients being prevented from experiencing a new ischaemic event.
Ved at forhindre denne sammenklumpning nedsætter en blodpropopløsende medicin risikoen for, at der dannes blodpropper (en proces, der kaldes trombose). 
By preventing this clumping, antiplatelet medicinal products reduce the chances of blood clots forming (a process called
Vigtig information om nogle af de øvrige indholdsstoffer i Clopidogrel Qualimed Clopidogrel Qualimed indeholder hydrogeneret ricinusolie, som kan give mavebesvær og diarré. 
Important information about some of the ingredients of Clopidogrel Qualimed Clopidogrel Qualimed contains hydrogenated castor oil which may cause stomach upset and diarrhoea.
Derfor bør samtidig administration af NSAID'er inklusive cox-2-hæmmere og clopidogrel foregå med forsigtighed (se pkt. 
Consequently, NSAIDs including Cox-2 inhibitors and clopidogrel should be co-administered with caution (see section 4.4).
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenien TAD Pharma GmbH, Heinz-Lohmann-Straße 5, 27472 Cuxhaven, Tyskland 
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia TAD Pharma GmbH, Heinz-Lohmann-Straße 5, 27472 Cuxhaven, Germany For any information about this medicine, please contact the local representative of the Marketing
Ved 300 mg/75 mg dosisregimet, var det trombocythæmmende respons nedsat hos personer med poor metabolisme med en gennemsnitlig IPA (5 µM ADP) på 24 % (24 timer) og 37 % (dag 5), sammenlignet med IPA på 39 % (24 timer) og 58 % (dag 5) for personer med extensive metabolisme, og 37 % (24 timer) og 60 % (dag 5) hos personer med intermediate metabolisme. 
After the 300 mg/75 mg dose regimen, antiplatelet responses were decreased in the poor metabolisers with mean IPA (5 μM ADP) of 24% (24 hours) and 37% (Day 5) as compared to IPA of 39% (24 hours) and 58% (Day 5) in the extensive metabolisers and 37% (24 hours) and 60% (Day 5) in the intermediate metabolisers.
Forekomsten af større blødninger var ensartet i de to grupper. 
The incidence of major bleeding was similar between groups.
Hyppigheden af klinisk signifikant blødning var den samme som den, der ses, når trombolytiske midler og heparin indgives samtidig med ASA (se pkt. 
The incidence of clinically significant bleeding was similar to that observed when thrombolytic agents and heparin are co-administered with ASA (see section 4.8).
De øvrige indholdsstoffer er: - Tabletkernen: mikrokrystallinsk cellulose, vandfri kolloid silica, crospovidon (type A), macrogol 6000, hydrogeneret ricinusolie, - Filmovertrækket: hydroxypropylcellulose (E463), titandioxid (E171), rødt jernoxid (E172), talcum og propylenglycol. 
- Tablet core: microcrystalline cellulose, colloidal anhydrous silica, crospovidone (type A), macrogol 6000, hydrogenated castor oil - Film-coating: hydroxypropylcellulose (E463), titanium dioxide (E171), red iron oxide (E172), talc and propylene glycol.
Retroperitoneal blødning 
Retroperitoneal haemorrhage
• Voksne patienter med myokardieinfarkt (fra få dage, men ikke over 35 dage), iskæmisk apopleksi (fra 7 dage, men ikke over 6 måneder) eller påviste perifere kredsløbsforstyrrelser. 
• Adults patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial
Ligesom andre antitrombolytika skal clopidogrel anvendes med forsigtighed til patienter med risiko for tiltagende blødninger pga. traumer, kirurgi eller andre patologiske tilstande samt til patienter, der samtidigt behandles med ASA, heparin, glycoprotein IIb/IIIa-hæmmere eller non-steroide antiinflammatoriske lægemidler (NSAID'er) inklusive cox-2-hæmmere. 
As with other antiplatelet agents, clopidogrel should be used with caution in patients who may be at risk of increased bleeding from trauma, surgery or other pathological conditions and in patients receiving treatment with ASA, heparin, glycoprotein IIb/IIIa inhibitors or non-steroidal anti-inflammatory drugs (NSAIDs) including Cox-2 inhibitors.
Hyppigheden af CYP2C19-alleler, der resulterer i moderat eller ringe CYP2C19-metabolisme, varierer afhængigt af race/etnisk tilhørsforhold (se farmakogenetik). 
The prevalence of CYP2C19 alleles that result in intermediate and poor CYP2C19 metabolism differs according to race/ethnicity (see Pharmacogenetics).
Serumsygdom, anafylaktiske reaktioner 
Serum sickness, anaphylactoid reactions
I CHARISMA og et ken kohortestudie (Simon), sås kun en øget hyppighed af hændelser hos personer med poor metabolisme, i sammenligning med personer med extensive metabolisme. 
In CHARISMA and one cohort study (Simon), an increased event rate was observed only in poor metabolisers when compared to extensive metabolisers.